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Preterm birth (born before 37 weeks of gestation) affects about 10% of pregnancies. 1 Chronic pulmonary complications of preterm birth are common, and include bronchopulmonary dysplasia (BPD) and asthma. 2, 3 Compared with children born full term, children born significantly preterm had about 3 times the risk of developing chronic wheezing and asthma disorders later in their lives. 4 The molecular and immunological mechanisms underlying the wheezing and asthma associated with prematurity are currently unclear.
At birth, infants born significantly preterm are likely to require life-supporting respiratory support with positive pressure ventilation and supplemental oxygen. Because the preterm lung is normally developed in a relatively hypoxic intrauterine environment, even exposure to room air (RA, 21% oxygen concentration) is considered hyperoxic and constitutes an oxidative stress. 5 Exposure to higher degrees and durations of hyperoxia results in significant neonatal lung injury, interrupted lung development, and ultimately the development of BPD. [6] [7] [8] The lungs of term newborn mice are developmentally and structurally comparable with the lungs of human infants born around 26 to 28 weeks' gestation. 9 Therefore, hyperoxia exposure of newborn mice offers a useful model for investigating the role of premature oxygen exposure in regulating lung development and chronic diseases in infants born very prematurely. Using a murine neonatal hyperoxia model, it has been shown that neonatal hyperoxia inhibited the development of alveolar-capillary membrane structure and impaired lung gas-exchange function, similar to findings observed in human BPD. 10, 11 Neonatal hyperoxia also alters lung inflammation status and immune cell compositions, 12 which may contribute to the enhanced inflammatory response against influenza virus infection in adult age. 13, 14 In addition, neonatal hyperoxia promotes airway hyperresponsiveness (AHR) to methacholine challenge, 15, 16 but the underlying molecular and cellular mechanisms were not investigated.
Innate lymphoid cells have recently been identified as innate counterparts of T H cells that are capable of secreting large amounts of cytokines upon stimulation. 17 On the basis of their cytokine secretion, innate lymphoid cells can be divided into 3 groups: group 1 innate lymphoid cells, which produce T H 1 cytokine IFN-g; group 2 innate lymphoid cells (ILC2s), which produce large amount of IL-5 and IL-13; and group 3 innate lymphoid cells, which secrete T H 17 cytokines IL-17 and IL-22. 17, 18 In the lungs, ILC2s appear to be the major ILC subset and respond to epithelial cell-derived cytokines including IL-25, IL-33, and thymic stromal lymphopoietin (TSLP). [19] [20] [21] Enhanced ILC2 activities have been observed in various murine asthma models and human clinical asthma studies. 22, 23 Interestingly, recent evidence shows that ILC2s are accumulated following spontaneous IL-33 release at the alveolar phase of lung development and contribute to the T H 2-mediated allergic asthma development later in life. 24, 25 To this end, ILC2s promote antigen uptake and dendritic cell (DC) migration to the lung-draining lymph nodes, thereby facilitating the induction of T H 2 responses against allergens. 24, 26 Thus, ILC2s appear to be one of the key drivers for innate and adaptive immunity in asthma development, particularly at the neonatal stages. However, it remains largely unclear whether neonatal ILC2 development and function are regulated by various external environmental factors (eg, hyperoxia), thereby influencing the development of pediatric asthma.
We found that neonatal hyperoxia promoted asthma-like immunologic and physiologic features in mice and further enhanced allergic T H 2 and T H 17 responses in the respiratory tract following allergen exposure. Neonatal hyperoxia promoted IL-33 expression in the developing lungs, and enhanced ILC2 expansion was required for the development of asthma-like features. The Nrf2 agonist sulforaphane (SFN) reduced lung IL-33 levels and ILC2 responses, supporting the role of oxidative stress in the promotion of ILC2s in the lung. Furthermore, genetic ablation of the IL-33 receptor ST2 decreased asthma-related gene expression, eosinophil recruitment, and ILC2 responses following neonatal hyperoxia. Finally, in preterm infants, we found that serum IL-33 levels positively correlated with serum IL-5 and IL-13, but not IL-4 levels. Our findings suggest that in infants experiencing oxidative stress as a result of premature birth, IL-33 and ILC2s may play an important role in promoting the development of asthma-related features.
METHODS

Ethics statement
All animal experiments were approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine and the Mayo Clinic.
Blood samples were obtained from infants who were born full term or premature following institutional review board approval and written parental consent.
Mouse and neonatal hyperoxia model 
Measurement of AHR
AHR to methacholine challenged was measured using the FinePoint RC system (Buxco Research Systems, Wilmington, NC), and the airflow was recorded in individual mice according to the manufacturer's guidelines. Briefly, mice were anesthetized and a tracheostomy tube was inserted and connected to a ventilator. After 5 minutes of stabilization followed by administration of PBS, airway resistance was determined by dose responsiveness to aerosolized methacholine (Sigma-Aldrich, St Louis, Mo) delivered by a nebulizer.
Lung single-cell preparation
For airway cells, bronchoalveolar lavage was obtained by flushing the airway multiple times with 400 mL aliquots of sterile PBS, followed by centrifugation to collect airway cells. For lung single-cell suspensions, lungs were perfused with PBS, chopped to small pieces using scissors, and digested with 5 mL of 183 U/mL collagenase type 2 (Worthington Biochemical Corporation, Lakewood, NJ). After 40 minutes, lung pieces were dispersed by passage through a 70-mM strainer and RBC lysed with ACK buffer. For cytokine detection in lung, lungs were mechanically separated by passage through a strainer, which was subsequently rinsed with 400 mL of PBS. After centrifugation, supernatants were collected to determine cytokine protein levels by ELISA.
Quantitative RT-PCR quantistudio 3 PCR system (Applied Biosystems). Data were generated by using the comparative threshold cycle (DCT) method by normalizing to hypoxanthine-guanine phosphoribosyltransferase. 
Epithelial cell culture
Determination of reactive oxygen species levels
To measure intracellular reactive oxygen species (ROS) levels in epithelial cells, lung single-cell suspensions were surface stained with antibodies conjugated with fluorescence (anti-CD45 and anti-EpCAM) first. Cells were then stained with 10 mM CM-H2DCFDA (Molecular Probes, Carlsbad, Calif) at 378C for 30 minutes. Cells were washed and analyzed immediately by flow cytometry. Cells that were treated with 50 mM of H 2 O 2 served as the positive control.
Flow cytometry
To quantify ILC2s, lung single cells were stained with fluorescentconjugated lineage markers (Lin: CD11b, CD11c, CD3, B220, Ter-119, Gr-1, NK1.1, TCRb), anti-Thy1.2, anti-CD25, anti-CD127, and anti-ST2. ILC2s were identified as Lin 2 Th1. 
ELISA
Cytokines in the supernatants of lung homogenates were measured with IL-33 ELISA kit (eBioscience) or TSLP ELISA kit (Biolegend) according to the manufacturer's instructions.
Histology
At PN day 28, whole lungs were harvested and fixed in 10% formaldehyde (Fisher Scientific, Fair Lawn, NJ) for 48 hours and stored in PBS until embedding. Fixed lung tissues were embedded in paraffin, sectioned at 5-mm thickness, and stained with hematoxylin and eosin or periodic acid-Schiff (PAS) by the Indiana University Pathology Laboratory. Histological scores (ranges, 1-4) were found on PAS-stained slides blindly by 2 independent observers. To quantify the percentage of areas stained with PAS within airway epithelium of lung specimens, computer-based image analysis was performed on the basis of a previous report. 27 Briefly, each image was set with scale bar as size per pixel using Image-Pro Premier 3D (Media Cybernetics, Rockville, Md). The areas of airway epithelium and the areas of PAS-positive airway epithelium were computer traced on the basis of differential colored pixels. PAS-positive areas in the epithelium and areas of total airway epithelium were recorded in randomly selected airway sections (;5) per lung tissue section. The percentage of PASpositive area was calculated on the basis of the ratio of PAS-positive areas to the total areas of airway epithelium in each lung section.
Clinical samples
Sera were collected from children at 3 to 30 months of corrected age who were born prematurely (<37 gestation week) or maturely and determined cytokine levels using multiplex (Millipore, Billerica, Mass) according to the manufacturer's instructions. All data points are from individual patients.
Statistical analysis
Data were expressed in mean values 6 SEM. 1-way ANOVA, 2-way ANOVA with subsequent Fishers Least Significant Difference (LSD) test, or t test was used to determine the significance of differences between groups using GraphPad Prism software. For clinical data, correlations were evaluated by Pearson test using GraphPad Prism (Graphpad, La Jolla, Calif).
RESULTS
Neonatal hyperoxia promotes AHR, mucus production, and type 2 airway inflammation
We have used a murine neonatal hyperoxia model to replicate the high concentration of oxygen (relative to the hypoxic levels experienced in utero) delivered to lungs of infants born preterm. 5, 28 To mimic the lung injury experienced by preterm infants, for the first 7 postnatal days we exposed neonatal mice to either hyperoxia (80% oxygen, O 2 ) or RA (21% oxygen) (Fig 1, A) . To understand the long-term effects of neonatal hyperoxia exposure, all mice were then housed in RA for an additional 21 days and their AHR assessed. Consistent with previous reports, 15, 16 we found that compared with mice raised entirely in RA, mice previously exposed to neonatal hyperoxia showed significantly higher AHR (Fig 1, B) . In line with our previous report, 29 histological analysis showed that lungs from O 2 -exposed mice had simplified alveolar structure (Fig 1, C) . Strikingly, neonatal hyperoxia exposure was associated with mucus hyperplasia (Fig 1, C-E ). In addition, lungs of O 2 -exposed mice displayed a significant increase in the expression of mucus-associated genes (Clca1 and Muc5ac) (Fig 1, F) . The expression of type 2 cytokines IL-5 and IL-13, but not IFN-g, IL-17, and IL-4, was also significantly increased in the lungs from O 2 -exposed mice, suggesting that these mice have enhanced type 2 airway inflammation (Fig 1, G) . Furthermore, mice exposed to neonatal hyperoxia also showed airway eosinophilia (Fig 1, H) . Interestingly, previous exposure to neonatal hyperoxia was also associated with airway neutrophilia (Fig 1, I) . Together, these results demonstrate that neonatal hyperoxia promotes the development of multiple cardinal features of asthma-like symptoms including AHR, mucus production, type 2 inflammation, and recruitment of eosinophils and neutrophils.
Neonatal hyperoxia leads to enhanced lung ILC2 responses at the pediatric stage
We sought to identify the cellular mechanisms underlying the development of AHR and type 2 inflammation associated with previous exposure to neonatal hyperoxia. To quantify IL-13-producing cells, we performed intracellular cytokine staining for single-cell suspensions obtained from lungs of RAor O 2 -exposed mice. Consistent with our gene expression data (Fig 1, F) , compared with lungs of RA-exposed mice, lungs of O 2 -exposed mice contained a significantly higher proportion of IL-13-producing cells (Fig 2, A-C) . Most IL-13-producing cells lacked CD4 expression (CD4 2 ) (Fig 2, A and B) , indicating that they were not T H 2 cells. ILC2s are recently identified, lineage-negative innate immune cells capable of producing large amounts of type 2 cytokines. 22 We found that most lung IL-13-producing cells were lineage-negative (Lin 2 ) (Fig 2, A and C) , suggesting that they are ILC2s. Indeed, these Lin 2 IL-13-producing cells also expressed CD25 and CD127 (see Fig E1 in this article's Online Repository at www.jacionline.org), further supporting their identity as ILC2s. Extensive surface-marker analysis confirmed the expression of ST2, ICOS, CD90, KLRG1, and low levels of IL-17RB, the typical markers of ILC2s (Fig 2, D) . In the lungs from RA-or O 2 -exposed mice at PN day 7, the relative frequency and absolute number of ILC2s were not different (Fig 2, E) . However, lungs of O 2 -exposed mice showed increased ILC2 frequency and/or FIG 1. Neonatal hyperoxia promotes AHR, mucus production, and type 2 airway inflammation. A, Experimental schemes. Neonatal mice were exposed to hyperoxia or RA for 7 days and then housed in RA until PN day 28 for analysis of AHR, histology, and lung inflammation. B, Airway resistance (R L ) was determined following methacholine (Meth) challenge in mice exposed to RA or O 2 . n 5 5 or 6 mice per group (mean 6 SEM). C, Lung sections were stained with hematoxylin and eosin (H&E) or PAS. D, Pathology scores on PAS staining sections were quantified. n 5 13 or 14 mice per group (mean 6 SEM). E, % of PAS-positive areas within airway epithelium was calculated by image analysis. n 5 13 or 14 mice per group (mean 6 SEM). F, Lung mucus-associated genes were measured by quantitative RT-PCR. n 5 3 or 4 mice per group (mean 6 SEM). G, Lung cytokine gene expressions were determined by quantitative RT-PCR. n 5 6 mice per group (mean 6 SEM). H, The frequencies and absolute numbers of eosinophils (CD45 1 SiglecF 1 CD11c
2 ) in BAL were measured by flow cytometry. n 5 3 mice per group (mean 6 SEM). I, The frequencies and absolute numbers of neutrophils (
were measured by flow cytometry. n 5 3 mice per group (mean 6 SEM). BAL, Bronchoalveolar lavage; HPRT, hypoxanthine-guanine phosphoribosyltransferase; n.s., not significant. Data are representative of at least 3 independent experiments. *P < _ .05.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 4 numbers than lungs of RA-exposed mice at PN day 14 and PN day 28 (Fig 2, E) . The levels of lung ILC2 responses were comparable between RA-and O 2 -exposed mice at PN day 58 (Fig 2, E) . O 2 -exposed mice also exhibited enhanced total DCs, FcεRI 
AHR and pulmonary type 2 inflammation are mediated by ILC2s
To determine the roles of ILC2s in the development of AHR and type 2 inflammation, we exposed Rag1 2/2 mice (deficient in T and B cells) and Rag2
2/2
/Il2rg
2/2 mice (deficient in T, B, and ILCs) to RA or neonatal hyperoxia (as in Fig 1, A) and measured AHR at PN day 28. Similar to WT mice, O 2 -exposed Rag1 2/2 mice showed increased airway responsiveness, suggesting that T and B cells are dispensable for AHR development following neonatal hyperoxia (Fig 3, A) 
2/2 mice was comparable to that in RA-exposed control mice and demonstrated diminished airway mucus production (Fig 3, B-E ) (Fig 3, F) . These data suggest that although T H 2 cells are dispensable, ILC2s are essential for the development of neonatal hyperoxiainduced AHR, mucous production, and type 2 inflammation.
Neonatal hyperoxia promotes allergic inflammation
Besides AHR, children and adolescents formerly born preterm exhibit enhanced development of allergic asthma. 30 In addition, preclinical murine models have established that ILC2s are capable of enhancing adaptive T H 2 responses following intranasal papain challenge. 26 We therefore hypothesized that mice formerly exposed to neonatal hyperoxia would demonstrate elevated allergic responses to subsequent airway allergen exposure. To test this, we administered HDM intranasally to RA-or O 2 -exposed WT mice for 4 weeks starting at PN day 28 and examined T H responses at PN day 56 (Fig 4, A) . We chose PN day 28 for HDM challenge because maximal differences in ILC2 responses between RA-and O 2 -exposed mice were observed at this time point (Fig 2, E) . As shown previously, 31, 32 chronic HDM exposure in both groups increased airway inflammation, eosinophilia, and neutrophilia (Fig 4, B) . However, HDM-challenged O 2 -exposed mice exhibited a significantly exaggerated response as evidenced by higher numbers of airway eosinophils and neutrophils compared with those of HDM-challenged RA-exposed mice. We also observed increased numbers of IL-4-, IL-13-, and IL-17-producing Lin 1 cells (Fig 2, B) or Lin 2 (Fig 2, C) were determined by flow cytometry. n 5 3 mice per group (mean 6 SEM). D, Expression of surface markers on ILC2s (Lin
) in mice exposed to RA or O 2 . E, The frequencies and absolute numbers of ILC2s in the lungs were measured at the indicated PN days. n 5 3 to 7 mice per group (mean 6 SEM). Data are representative of at least 2 independent experiments. *P < _ .05. FACS, Fluorescence-activated cell sorting; FMO, fluorescence minus one; ICOS, inducible T-cell costimulator; n.s., not significant. present in the airway (Fig 4, C and D) and increased IL-13-producing cells in the lungs (see Fig E3 in this article' s Online Repository at www.jacionline.org) of HDM-challenged O 2 -exposed mice compared with lungs of HDM-challenged RA-exposed mice. At PN day 56, both at baseline (Fig 2, E) and following HDM exposure, the frequencies and absolute numbers of ILC2s between RA-and O 2 -exposed groups were not different (see Fig E4 in this article' s Online Repository at www.jacionline. org). Notably, most IL-17-producing cells following HDM challenge were Lin 1 (Fig E3) , indicating that T cells rather than ILC3s were likely the main IL-17-producing cells following HDM challenge in both RA-and O 2 -exposed mice. Together, these data indicate that exposure of neonates to hyperoxia later exacerbates the development of allergic inflammation following respiratory allergen challenge.
Activation of the antioxidant pathway attenuates IL-33 and ILC2 responses
To explore the molecular mechanisms that drive enhanced ILC2 responses and type 2 inflammation resulting from neonatal hyperoxia exposure, we examined the expression of epithelial-derived cytokines including IL-25, IL-33, and TSLP, which have been shown to be important for inciting ILC2 responses. 20 In the lungs of O 2 -exposed mice at the conclusion of neonatal hyperoxia exposure (PN day 7) and following 7 days of recovery in RA (PN day 14), mRNA expression of Tslp and Il33 was increased, respectively (Fig 5, A) . Although TSLP protein levels were undetectable in both RA-and O 2 -exposed lungs, in the lungs of O 2 -exposed mice we verified increased levels of IL-33 protein at PN day 21 (Fig 5,  B) . We did not observe measurable IL-33 in bronchoalveolar lavage fluid (data not shown), possibly because of the immediate depletion of the low levels of IL-33 produced following O 2 exposure. Hyperoxia can increase oxidative stress via the accumulation of ROS. 33 We found that oxidative stress genes were upregulated and epithelial cell ROS production was increased in lungs previously exposed to neonatal hyperoxia (see Fig E5, A and B, in this article's Online Repository at www.jacionline.org), suggesting that O 2 -exposed lungs exhibited increased oxidative stress. To test the hypothesis that oxidative stress facilitates Il33 expression, we exposed mouse airway epithelial cells to H 2 O 2 in vitro and then determined Il33 (Fig 5, C) . Treatment with H 2 O 2 increased Il33 expression in epithelial cells (Fig 5, C) . Nrf2 is a major transcription factor regulating cellular antioxidant responses 34, 35 and its agonist SFN has been used to attenuate oxidative stress and associated inflammation. 36 Fig 1, A, and airway resistance (R L ) was determined at PN day 28. n 5 4 to 11 mice per group (mean 6 SEM). B and C, Lung sections were stained with hematoxylin and eosin (Fig 3, B) or PAS (Fig 3, C) . D, Pathology scores on PAS staining sections were quantified. n 5 9 or 10 mice per group (mean 6 SEM). E, % of PAS-positive areas within airway epithelium was calculated by image analysis. n 5 9 or 10 mice per group (mean 6 SEM). F, The frequencies and absolute numbers of airway eosinophils were measured by flow cytometry. n 5 4 mice per group (mean 6 SEM). Data are representative of at least 2 independent experiments. *P < _ .05. Meth, Methacholine; n.s., not significant. J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 4 attenuate Il33 expression in epithelial cells (Fig 5, D) . Consistent with this notion, epithelial cells cultured under hyperoxia conditions exhibited enhanced Il33 expression in vitro, which was dampened by SFN treatment (Fig 5, E) . Importantly, treatment of mice with SFN in vivo during neonatal hyperoxia attenuated the upregulation of a number of oxidative stress genes (Fig E5, B) and impaired the observed increase in IL-33 protein levels following neonatal hyperoxia (Fig 5, F) . IL-33 has been shown to be a major driver of neonatal ILC2 expansion. 24 We therefore examined ILC2 responses following SFN treatment. Although SFN treatment tended to increase baseline ILC2 levels in RAexposed mice, treatment of SFN in O 2 -exposed mice blunted the observed increase in both ILC2s and Lin 2 /IL-13-producing cells at PN day 28 following hyperoxia ( Fig 5, G and  H) . Taken together, these data indicated that oxidative stress resulting from neonatal hyperoxia enhances IL-33 expression during recovery, which may contribute to expansion and activation of ILC2s.
ILC2 responses following neonatal hyperoxia are mediated by IL-33 signaling
To determine whether IL-33 signaling is required for type 2 lung inflammation and ILC2 responses following neonatal hyperoxia, we exposed WT and IL-33 receptor-deficient (ST2 2/2 ) mice to RA or neonatal hyperoxia (as in Fig 1, A) and assessed lung gene expression and ILC2 responses at PN day 28 (Fig 6) . Using allergy and asthma PCR-gene array, whole-lung RNA from O 2 -exposed WT mice showed increased expression of many asthma-related genes compared with whole-lung RNA of RA-exposed WT mice. Strikingly, most upregulated genes observed in O 2 -exposed WT mice were not upregulated similarly and remained similar to RA-exposed levels in lungs of O 2 -exposed ST2-deficient mice (Fig 6, A; see Fig E6 in this article's Online Repository at www.jacionline.org), suggesting that IL-33 signaling is an important contributor to the altered allergy and asthma gene expression profiles following neonatal hyperoxia. A number of differentially expressed genes including Arg1, Il21, Il5, Il13, Pmch, and Rnase2a were confirmed with RT-PCR (Fig 6, B) . Furthermore, compared with O 2 -exposed WT mice, O 2 -exposed ST2-deficient mice showed diminished frequency and number of ILC2s in the lungs, suggesting that following neonatal hyperoxia, IL-33 signaling is critical for the expansion of ILC2s (Fig 6, C) . Following neonatal hyperoxia, both IL-13-and IL-5-producing ILC2s were significantly decreased in the absence of IL-33 signaling (Fig 6, D) . Consistent with diminished ILC2s in the lungs, ST2-deficient mice failed to develop airway eosinophilia in response to neonatal hyperoxia (Fig 6, E) . Together, these results suggest that IL-33 signaling via ST2 is critically important for the expression of asthma-related genes, ILC2 responses, and airway inflammation following neonatal hyperoxia. 
Serum IL-33 levels correlate with IL-5 and IL-13 levels in preterm infants
To determine whether the relationship between IL-33 and type 2 cytokines established in the mouse model is conserved in preterm infants, we analyzed the levels of IL-33 and type 2 cytokine concentrations in sera obtained from children (aged 3-30 months) who had been born either term or preterm (see Table  E1 in this article's Online Repository at www.jacionline.org). Likely because of the limited sample size and varied sample collection time point, the levels of IL-33 and type 2 cytokines such as IL-5, IL-13, and IL-4 in the sera of preterm infants were not significantly different from those of term infants (see Fig E7, A, in this article's Online Repository at www.jacionline. org), although we observed a trend toward increased percentages of individuals having high serum IL-33 levels in preterm infants, particularly in those infants who met criteria for BPD (Fig E7, B) . We also observed a trend toward increased percentages of individuals having high serum IL-33 levels in the group of infants born before 30 weeks' gestation (Fig E7, C) . Interestingly, there was a significant correlation between serum concentrations of IL-33 and IL-5 and serum concentrations of IL-33 and IL-13 within the preterm group (Fig 7, A and B) but not in the term infant group (see Fig E8 in this article' s Online Repository at www.jacionline.org). In addition, we found that there were significant correlations between serum IL-33 and IL-13 and serum IL-33 and IL-5 levels in sera collected in infants younger than 18 months, but not in sera collected from infants aged between 18 and 30 months (see Fig E9 in this article' s Online Repository at www.jacionline.org).
Although IL-4 production by ILC2s has been described, unlike IL-13, it is not required for induction of T H 2 responses. 26, 38 We found that serum IL-33 levels did not significantly correlate with serum IL-4 levels in preterm infants (Fig 7, C) . The sum of these clinical data corroborates our findings in the preclinical neonatal hyperoxia model: following hyperoxia, we observed increased IL-5 and IL-13 in association with increased IL-33, ) . B, Cytokine protein levels were determined by ELISA in the lung supernatants at PN day 21. n 5 3 mice per group (mean 6 SEM). C, MLE-12 cells were exposed to different concentrations of H 2 O 2 . Il33 gene expression was determined by quantitative RT-PCR. n 5 2 per group (mean 6 SEM). D, MLE-12 cells were exposed to H 2 O 2 of 200 mM in the presence or absence of SFN, and Il33 gene expression was determined by quantitative RT-PCR. n 5 2 per group (mean 6 SEM). E, MLE-12 cells were cultured under normoxia or hyperoxia condition for 24 hours in the presence or absence of SFN and then recovered in normoxia incubator for an additional 24 hours. Il33 expression was determined by quantitative RT-PCR. n 5 3 per group (mean 6 SEM). F, Neonatal mice were exposed to RA or O 2 and treated with SFN. IL-33 protein levels were measured at PN day 21. n 5 2 or 3 mice per group (mean 6 SEM). G and H, Neonatal mice were exposed to RA or O 2 and treated with SFN. Total ILC2 (Fig 5, G) or IL-13 1 ILC2 numbers were determined at PN day 28. n 5 4 or 8 mice per group (mean 6 SEM). Data are representative of at least 2 independent experiments. *P < _ .05. HPRT, Hypoxanthine-guanine phosphoribosyltransferase; n.s., not significant.
which is required for ILC2 expansion. Thus, although future studies on respiratory IL-33 and type 2 cytokine levels in preterm infants with larger sample sizes are warranted, these data suggest the proof of principle that an IL-33-ILC2 axis could be a reasonable contributor of asthma-like airway inflammation in preterm infants.
DISCUSSION
Infants born extremely premature often require supplemental oxygen therapy for their survival. However, in preterm infants and in preclinical animal models, oxygen supplementation has been associated with interrupted distal lung development, chronic deficits in gas exchange, airway hyperreactivity, and chronic pulmonary dysfunction. [39] [40] [41] Numerous studies have established various detrimental effects of neonatal hyperoxia on lung structural and functional development. 28, 42, 43 However, the mechanisms by which neonatal hyperoxia mediates pulmonary inflammation, abnormal lung development, and chronic pulmonary dysfunction are largely unknown. We show here that neonatal hyperoxia enhanced lung IL-33 production and ILC2 responses, thereby resulting in AHR, mucous production, and type 2 inflammation. Strikingly, we found that neonatal hyperoxia also exaggerated pulmonary allergic responses to respiratory allergen challenge. Our findings suggest that an axis involving IL-33 and ILC2s is vital for the development of asthma-related pathology following neonatal hyperoxia.
Our observation that young-adult mice previously subjected to neonatal hyperoxia for the first 7 PN days (the period of saccular and rapid alveolar development) show that AHR is in agreement with previous studies of a similar developmental window. 15, 44 We further demonstrated here that neonatal hyperoxia promoted the development of other asthma-like features including mucus production, airway eosinophilia, and neutrophilia and increased expression of type 2 cytokines IL-5 and IL-13. Thus, neonatal hyperoxia leads to the development of multiple asthma-like features at the pediatric and young-adult stages. These results are consistent with the data that asthma-like symptoms and AHR are frequently reported in children, adolescents, and young adults who were born very premature and developed BPD. [45] [46] [47] Notably, neonatal T cells are prone to developing into T H 2-type cells following infection or antigenic challenge via T-cell-intrinsic and extrinsic mechanisms. [48] [49] [50] It is thus of interest that ILC2s, rather than T H 2 cells, are increased in the lungs and required for the development of asthma-like symptoms following neonatal hyperoxia. Although atopic asthma driven by T H 2 cells is responsive to specific antigens or allergens, ILC2s that are driven by hyperoxia are unlikely responsive to specific antigens but driven by cytokines released by reactive epithelial cells. This difference may underlie the fact that some features of asthma and AHR subsequent to extremely premature birth differed from typical allergic childhood asthma. 51 In addition to AHR and type 2 inflammation, we found that neonatal hyperoxia also increased host sensitivity to allergen challenge as reflected by elevated type 2 and type 17 inflammation observed in the lungs following HDM challenge. Notably, previous findings have found that neonatal hyperoxia did not enhance allergic responses to ovalbumin challenge. 15 This could be due to differences in allergens or sensitization routes used as ovalbumin was given intraperitoneally previously, 15 whereas HDM was delivered intranasally in our study. ILC2s have been shown to facilitate sensitization to local, but not systemic, T H 2-inducing allergen exposures. 52 Thus, it is possible that enhanced ILC2 responses following neonatal hyperoxia specifically enhance respiratory, but not systemic, allergen sensitization. Consistent with this concept, IL-13 derived from ILC2s was shown to enhance allergic responses through the promotion of DC migration to lung-draining mediastinal lymph nodes for the priming of naive CD4 T cells. ILC2s have also been shown to mediate memory T H 2 cell activation 53 and can acquire memory-like properties to enhance allergic lung inflammation months after their initial activation. 54 Thus, ILC2s could be a central regulator in the induction of both innate and adaptive immunity during the development of AHR and allergic asthma in response to allergens in infants born prematurely. Future studies are warranted to establish the specific roles and underlying mechanisms by which ILC2s may play to promote T H 2 and T H 17 responses following neonatal hyperoxia.
Airway epithelial-derived IL-25, TSLP, and IL-33 have been shown to enhance ILC2 expansion and/or cytokine production. 21, [55] [56] [57] [58] [59] We found that IL-25 expression was comparable between RA-and O 2 -exposed mice, suggesting that for the induction of enhanced ILC2 responses following neonatal hyperoxia, IL-25 is unlikely to be vital. Conversely, both TSLP and IL-33 transcription in the lung was enhanced following neonatal hyperoxia. Although the effects of TSLP on ILC2 responses are not tested in our study, data observed here have suggested a critical role of IL-33 in promoting ILC2 responses and type 2 inflammation following neonatal hyperoxia, because ST2 deficiency impaired ILC2 expansion and cytokine production. Strikingly, ST2 deficiency diminished the expression of a large number of asthma-related genes, indicating that the IL-33-ST2 signaling axis is critical for the development of asthma-like inflammation in the lung following neonatal hyperoxia. Of note, the effects of ST2 signaling in other cell types, including eosinophils, have been documented. 60 Future studies, therefore, are needed to investigate the exact roles of IL-33 signaling in ILC2s in promoting asthma-related gene expression in the lungs. Two recent studies have shown that IL-33 is released spontaneously during lung alveolarization, which drives enhanced ILC2 accumulation and asthma development at the pediatric stage. 24, 25 Our results are consistent with those findings because we also observed that ILC2 percentages in the lungs reached a peak at PN day 14 in mice housed under RA. However, hyperoxia exposure further enhanced and sustained IL-33 expression, which further promoted and sustained lung ILC2 responses till PN day 28. Because IL-33 production by epithelial cells is associated with lung remodeling during distal lung development, it is possible that aberrant lung alveolarization and a sustained lung remodeling process may contribute to the prolonged IL-33 expression following neonatal hyperoxia. 24 Our present data lead us to postulate that cellular oxidative stress may be an important factor in the production of IL-33. Increased ROS levels have been shown to contribute significantly to lung injury, 61 and Nrf2 agonists given in the course of neonatal hyperoxia have been shown to dampen lung injury and promote normal distal lung development. 62 Consistent with this idea, the Nrf2 agonist SFN dampened IL-33 expression in vitro and in vivo and decreased ILC2s in the lungs of O 2 -exposed mice. Interestingly, stimulation of the Nrf2 pathway appeared to elevate ILC2 responses in RA-control mice at baseline. Thus, it is plausible that the beneficial effects of SFN on ILC2 responses following neonatal hyperoxia could be partially masked. To this end, a recent article has suggested that oxidative stress is a key checkpoint for IL-33 release by airway epithelium. 27 Interestingly, because of interruption of placental-fetal transfer and inadequate endogenous production, antioxidant responses are compromised in preterm infants. 63, 64 Furthermore, following ovalbumin challenge in the adult age, Nrf2 agonists have been shown to inhibit T H 2 responses and asthma development. 65 Thus, targeting oxidative stress with proper antioxidants could be a promising method to prevent airflow obstruction and asthma development commonly observed following preterm birth.
As a proof of principle, we measured serum IL-33 and type 2 cytokine levels in older infants formerly born preterm and compared them with age-matched term-born infants. Although compared with term infants there is a trend that IL-33 concentrations are elevated in the sera of infants born prematurely, the differences did not reach statistical significance most likely because of the small sample size. However, we observed that there is a significant correlation between serum IL-33 and serum IL-5 and IL-13 levels in preterm infants. Unlike IL-13, ILC2-derived IL-4 is not required to induce T H 2 responses. 26 Thus, these data provide a proof of principle that IL-33-driven ILC2 responses may be relevant in the development of asthma-like symptoms observed in those of preterm infants. Indeed, IL-33 has been increasingly appreciated as a major driver of human asthma. 66, 67 Notably, IL-33 activity is regulated by multiple posttranslational events including protease cleavage and oxidization. 68 The IL-33 levels measured here did not differentiate the active versus nonactive forms. Furthermore, we measured circulating rather than respiratory IL-33 because of the lack of accessibility to respiratory samples. To firmly establish the roles of IL-33 in asthma development in preterm infants, active forms of respiratory IL-33 levels should be analyzed in the future.
Extremely preterm infants in the postsurfactant era are exposed to lower degrees of hyperoxia than previously. Therefore, given the significant change in clinical practice and disease phenotype, animal models using excessive hyperoxia should be assessed for their clinical relevance. We chose to use 80% oxygen because, as we have previously published, similar levels of hyperoxia produce a durable phenotype that structurally and functionally mimics many of the aspects of postsurfactant BPD. 11, 29 Recent clinical reports of extremely premature infants have consistently suggested a dose-response effect with oxygen support and lung function. For example, in infants and children previously diagnosed with BPD, the duration of oxygen supplementation and deficits in FEV 1 and DLCO were positively correlated. 6, 69, 70 Likewise, the severity of BPD and the degree of persistent lung dysfunction are also positively correlated. [71] [72] [73] Indeed, even in premature infants who did not develop BPD, early, cumulative oxygen exposure is predictive of persistent pulmonary dysfunction. 7 Although present-day neonatal care strives to reduce oxygen exposure to the lowest effective dose, many infants with significant early and persistent lung disease are routinely exposed to 40% to 50% oxygen on average, and many are exposed to 60% to 70% or higher. 8, [74] [75] [76] Thus, although careful oxygen titration has emerged as a centerpiece of neonatal care, many infants continue to require excessive oxygen supplementation, the degree of which generally correlates with persistent lung dysfunction. As with any animal model, direct comparison to the human condition is often complex. Given that the murine lung is designed to develop in an environment that is relatively hyperoxic compared with the human lung at the same stage, it is likely that higher levels of hyperoxia are required to injure the murine lung to a similar degree. Although we have not systematically investigated the above-mentioned possibilities, we justify our use of the current model on the basis of its ability to phenocopy some of the hallmark structural and functional characteristics of present-day BPD. 11, 29 In conclusion, our studies have revealed that neonatal hyperoxia promotes the development of asthma-like features and enhances host reactivity to respiratory allergen. We thus have provided viable cellular and molecular mechanisms explaining enhanced asthma development in children born prematurely. Our results suggest that targeting the IL-33 and ILC2 axis may be a reasonable future approach to prevent asthma development and/or treat asthma-like symptoms in children born prematurely.
